FOXO4-DRI Dosage: 8.30 mg or 11.41 mg in a 10 mg Vial

A dose is not simply a number somebody has used. It is a number that survived dose-ranging, pharmacokinetic sampling, a safety review and a regulator. Every one of those steps is missing for this compound.

FOXO4-DRI holds no authorisation from the FDA, the EMA or the MHRA. No phase 1 study has established how it behaves in a human body, so there is no measured half-life, no bioavailability figure, no clearance route and no maximum tolerated dose. Charts circulating online were produced by extrapolating from rodent experiments, and a chart with no measurement behind it is decoration.

What follows instead is the part that is genuinely computable: how much peptide is actually in the vial, and what concentration you get when you add solvent to it.

Reconstitution arithmetic is trivial. Mass divided by volume gives concentration. The difficulty is that the mass most people use is the number printed on the label, and for this product that number has not matched either published assay.

Kovera Labs certified batch 55-05260628 on 15 June 2026: 99.411% purity, net content 11.41 mg. MZ Biolabs analysed lot 55-01260229 on 10 January 2026: 99.97% purity, net content 8.30 mg. Both vials carried a 10 mg label, and both assays were excellent on purity. Purity and quantity are separate measurements, and it is quantity that moved.

Read the bottom row against the top. Someone holding the January batch and calculating from the label is carrying a concentration error of roughly 17%, and every volume drawn from that vial inherits it. No amount of careful measurement downstream corrects a wrong starting mass.

The instruction that follows is simple: use the net content from the certificate matching the lot number on your vial. If you were not given a lot-matched certificate, ask for one. Our FOXO4-DRI calculator will handle the conversion accurately once you give it the correct figure.

The same variance makes cost per milligram softer than the headline suggests.

That is a spread of about 37% on the figure every competing page quotes as a single confident number. It runs in the buyer's favour on one batch and against them on the other, which is worth stating plainly rather than framing purely as a warning.

The practical conclusion is that per-milligram price is a weak comparison metric for this compound specifically. If you are comparing suppliers on cost, compare assayed content, not labels.

For completeness, because the question behind the search deserves a real answer rather than a refusal.

In the foundational 2017 study, mice received FOXO4-DRI at 5 mg/kg, three times on alternating days, on days 1, 3 and 5. Administration was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts. Doxorubicin, used to induce senescence in that model, was given separately at 10 mg/kg in mice.

Two things about that schedule are routinely misreported. It was intermittent, three doses over five days rather than an ongoing course, because a senolytic aims to clear a cell population and then stop. And the routes used are laboratory routes in laboratory animals.

Body-weight scaling from that figure is a calculation you can perform and not a dose you can rely on. Allometric scaling estimates a starting point for formal study, and it requires pharmacokinetic inputs that do not exist for this peptide in humans. A D-retro-inverso construction is specifically designed to resist protease degradation, which is likely to alter persistence relative to an ordinary peptide, and by how much in a person is unstudied.

The lyophilised powder is the stable form, which is why it ships dry and why a parcel arriving at ambient temperature is not a problem. Kept cool, dark and sealed, dry peptide is comparatively durable.

Bacteriostatic water rather than sterile water is what allows repeated withdrawals from one vial, because it contains a preservative. Direct the solvent against the vial wall and swirl rather than shaking: mechanical agitation denatures peptides.

Once in solution the stability picture changes and the material belongs refrigerated, protected from light, and used within a much shorter window. Freeze-thaw cycles degrade it further.

None of this is dosing guidance. It is handling, and it applies to this the same way it applies to any research compound covered in our reconstitution calculators.

One conceptual point, because it explains the shape of the animal protocol and heads off a common misreading.

Most compounds are dosed continuously to hold a pathway suppressed or a receptor occupied. Stop and the effect fades. A senolytic is not maintaining anything. It eliminates senescent cells, and once they are gone there is nothing further to act on until they re-accumulate, which takes months to years rather than hours.

That is why the published work used a short burst. Continuous exposure would add whatever risk the compound carries without a corresponding benefit, and selectivity is relative rather than absolute, so more exposure means more opportunity to affect cells that were not the target.

It is also why importing cycle vocabulary from performance pharmacology misdescribes what is happening.